title: One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study.
abstract: OBJECTIVE
  To evaluate individualized intravitreal aflibercept regimens for treatment of neovascular age-related macular degeneration (nAMD)-related pigment epithelial detachment (PED).
  
  
  METHODS
  This prospective, multicenter, nonrandomized study included 32 eyes with nAMD-related PED, treated with ranibizumab for ≥6 months. All patients received intravitreal aflibercept (2 mg/0.05 mL) at baseline (no loading phase) and subsequently treated pro re nata with monthly follow-up for 12 months. Outcome measures included visual acuity, central retinal thickness (CRT), PED height and area, and neovascular network size.
  
  
  RESULTS
  At 12 months, aflibercept improved mean best-corrected visual acuity compared with baseline values (p&gt;0.05); 50% of patients displayed complete resolution of intraretinal and/or subretinal fluid. Compared with baseline, significant decreases were observed for mean CRT and PED height (both p&lt;0.01).
  
  
  CONCLUSIONS
  Aflibercept appears to induce anatomical improvement for at least 12 months after conversion from ranibizumab in patients experiencing nAMD-related PED. Significant reductions in both mean PED height and CRT were observed, although these changes were not necessarily related to significantly improved visual acuity scores. However, larger patient cohorts are required to extend and validate our results, and increased study duration would allow exploration of the potential long-term benefits and challenges of prolonged aflibercept use.
authors: Department of Medical and Biological Sciences-Ophthalmology, University of Udine, Udine - Italy.|European Institute of Ocular Microsurgery (IEMO), Udine - Italy.
authors: Daniele
authors: D
authors: Veritti
authors: Department of Medical and Biological Sciences-Ophthalmology, University of Udine, Udine - Italy.|European Institute of Ocular Microsurgery (IEMO), Udine - Italy.
authors: Valentina
authors: V
authors: Sarao
authors: Department of Ophthalmology, Fondazione G.B. Bietti-IRCCS, Rome - Italy.
authors: Mariacristina
authors: M
authors: Parravano
authors: Department of Ophthalmology, University of Barcelona, Bellvitge University Hospital, Barcelona - Spain.
authors: Luis
authors: L
authors: Arias
authors: Department of Ophthalmology, Fondazione G.B. Bietti-IRCCS, Rome - Italy.
authors: Monica
authors: M
authors: Varano
authors: Department of Medical and Biological Sciences-Ophthalmology, University of Udine, Udine - Italy.|European Institute of Ocular Microsurgery (IEMO), Udine - Italy.
authors: Paolo
authors: P
authors: Lanzetta
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D055213:Retinal Pigment Epithelium / Q000187:drug effects* / Q000473:pathology; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor